243 related articles for article (PubMed ID: 23922481)
1. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.
Wang Z; Chen JQ; Liu JL; Qin XG; Huang Y
World J Gastroenterol; 2013 Aug; 19(29):4808-17. PubMed ID: 23922481
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.
Zhu D; Wang L; Zhang H; Chen J; Wang Y; Byanju S; Liao M
Medicine (Baltimore); 2017 Aug; 96(33):e7813. PubMed ID: 28816978
[TBL] [Abstract][Full Text] [Related]
3. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis.
Tang S; Huang G; Liu J; Liu T; Treven L; Song S; Zhang C; Pan L; Zhang T
Eur J Radiol; 2011 Apr; 78(1):142-50. PubMed ID: 19854016
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis.
Rijkers AP; Valkema R; Duivenvoorden HJ; van Eijck CH
Eur J Surg Oncol; 2014 Jul; 40(7):794-804. PubMed ID: 24755095
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
7. 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Treatment Efficacy and Clinical Outcome for Patients With Pancreatic Carcinoma: A Meta-analysis.
Wang L; Dong P; Shen G; Hou S; Zhang Y; Liu X; Tian B
Pancreas; 2019 Sep; 48(8):996-1002. PubMed ID: 31404025
[TBL] [Abstract][Full Text] [Related]
8. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ
Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034
[TBL] [Abstract][Full Text] [Related]
11. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
[TBL] [Abstract][Full Text] [Related]
12.
Lamarca A; Barriuso J; Chander A; McNamara MG; Hubner RA; ÓReilly D; Manoharan P; Valle JW
J Hepatol; 2019 Jul; 71(1):115-129. PubMed ID: 30797051
[TBL] [Abstract][Full Text] [Related]
13. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
16. The utility of
Zhang Q; Xi Y; Li D; Yuan Z; Dong J
J Orthop Surg Res; 2020 Jun; 15(1):229. PubMed ID: 32571371
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis.
Sun DW; An L; Wei F; Mu L; Shi XJ; Wang CL; Zhao ZW; Li TF; Lv GY
Abdom Radiol (NY); 2016 Jan; 41(1):33-41. PubMed ID: 26830609
[TBL] [Abstract][Full Text] [Related]
18. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
[TBL] [Abstract][Full Text] [Related]
19. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
